Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Southern Medical Univ. HDAC6 compound 9q
- Development stage
- Unknown
- Lead developer
- Southern Medical University
01
Overview
Southern Medical Univ. HDAC6 compound 9q: sourced facts only. name: "The mechanism study revealed that 9q not only repressed tubulin polymerization, disrupted cellular microtubule networks but also inhibited HDAC6." [PMID:41351923]; target: "The mechanism study revealed that 9q not only repressed tubulin polymerization, disrupted cellular microtubule networks but also inhibited HDAC6." [PMID:41351923]; developer: "Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China." [PMID:41351923]; stage: "Most importantly, 9q effectively inhibited tumor growth in the HCT116 xenograft model without apparent toxicity." [PMID:41351923]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Southern Medical Univ. HDAC6 compound 9q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Southern Medical Univ. HDAC6 compound 9q.